Print Friendly, PDF & Email

NCT/Study#

NCT04050436 /

RPL-002-18

A Randomized, Controlled, Open-Label, Phase 2 Study of Cemiplimab as a Single Agent and in Combination With RP1 in Patients With Advanced Cutaneous Squamous Cell Carcinoma

DISEASE GROUP:

Skin and Soft Tissue

current phase:

Phase II

STUDY STATUS:

Accepting Patients

Location:

Hackensack, NJ

For More information:

Call 201-518-3587